- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
Angiogenesis and Arteriogenesis in Cardiac Hypertrophy |
263 |
7. Exercise-Induced Hypertrophy
Endurance training (aerobic exercise) increases cardiac work and O2 demand and has been shown by many studies to stimulate coronary angiogenesis (see reviews in Refs. 66 to 68). In the absence of cardiac hypertrophy, angiogenesis increases vascular density and may increase maximal myocardial perfusion/unit heart weight above that of controls. Most studies have shown that when exercise training evokes cardiac hypertrophy that sufficient coronary angiogenesis occurs and is fully compensatory.8,44,69−78 Capillary growth, the parameter most often addressed by these studies, paralleled the increase in cardiac mass in the left or right ventricle was documented in rats,69,77,79,80 pigeons81 and pigs.82
That capillary growth, as evidenced by an increase in numerical capillary density, may exceed the magnitude of ventricular hypertrophy induced by exercise training has also been reported in several studies.70,76,80,83 It appears that the magnitude of hypertrophy is not the key determinant of capillary growth since a 65% exercise-induced increase in heart mass had a minimal effect on intercapillary distance; a 27% increase in capillary diameter maintained volume density despite a 22% reduction in numerical density.84 However, two studies have shown that capillary density in the right ventricle and interventricular septum declines after strenuous exercise training.18,77 In contrast, training that was more moderate in intensity and of a shorter duration (seven weeks) enhanced capillary density in the right ventricle.70
The supposition that exercise-induced cardiac hypertrophy provides a stimulus for growth of pre-capillary vessels sufficient to preserve coronary reserve is supported by data from both myocardial perfusion and morphometric studies. Coronary flow capacity was increased in rats78 and pigs with exercise-induced cardiac hypertrophy.43,85 That enhancement of coronary vascular reserve associated with exercise training is independent of cardiac hypertrophy was demonstrated by Buttrick et al.73 An eight week swimming program enhanced vascular reserve in both male and female rats even though only the females developed cardiac hypertrophy. Arteriolar growth was also documented in pigs with cardiac enlargement ranging from <15% to >30%. Taken together, these studies indicate that exercise training of the appropriate
264 R. J. Tomanek & E. I. Dedkov
intensity provides stimuli(us) for coronary angiogenesis and arteriogenesis. The most likely stimulus for angiogenesis/arteriogenesis in this model appears to be increased blood flow and shear stress.
8. Myocardial Infarction-Induced Hypertrophy
Acute myocardial infarction (MI) results in the sudden death of a great number of cardiac myocytes. To preserve cardiac function, non-infarcted myocytes of the surviving myocardium, which experienced a chronic functional overload, undergo a reactive compensatory hypertrophy.57,86−98 Experimental studies have shown that surviving cardiac myocytes grow in length, as well as in diameter; the magnitude of this reactive hypertrophy is mainly determined by the size of infarct.57,88,90,92−101 The progressive increase in myocyte transverse areas affects a reduction in capillary density, and consequently, increases O2 diffusion distance.90−92,95,97,98,102−104 However, the decreased capillary density is not caused by loss of capillaries per se since capillary to myocyte ratio in the surviving, hypertrophied myocardium is unchanged. Moreover the fact that some capillary growth occurs is supported by work documenting absolute increases in the capillary bed, i.e. increased aggregate capillary length and increases in capillary/myocyte ratio (Table 3). Taken together, these findings demonstrate that the reduction in capillary parameters often detected in the surviving myocardium of post-infarcted hearts is not a consequence of the absence of capillary growth, but it is rather a failure of sufficient capillary bed expansion to match cardiomyocyte enlargement.
Although one study reported that maximal myocardial perfusion is normalized three weeks after myocardial infarction,105 data from our laboratory and others document marked reductions in maximal myocardial perfusion as well as in coronary reserve, in the surviving myocardium of rats between three and eight weeks after infarction.93,101,105−109 Since a strong correlation between minimal coronary resistance and myocyte cross-sectional area was documented,93 it was assumed that the depression in myocardial perfusion was primarily related to the ongoing hypertrophic process. This
Angiogenesis and Arteriogenesis in Cardiac Hypertrophy |
265 |
Table 3. Angiogenesis and arteriogenesis in myocardial infarction-induced |
|
hypertrophy.
Reference |
|
Species |
|
no(s). |
Magnitude of hypertrophy |
and age |
Vascular growth |
|
|
|
|
101 |
VW and VW/BW unchanged |
Rat |
LV arteriolar LV ↑ |
|
LV myocyte CSA in ↑ subendo |
12 |
|
|
and ↑subepi |
months |
|
96 |
HW, LVW and LVW/BW |
Rat |
Capillary NA in ↑ |
|
unchanged |
9 weeks |
subendo and ↑ subepi |
|
LV myocyte CSA in ↑subendo |
|
C/M ratio in ↑ subendo |
|
and ↑subepi |
|
and ↑subepi |
105 |
HW and HW/BW unchanged |
Rat |
Normal MCVP in |
|
in 3-week MI |
270– |
3-week MI |
|
|
320 g |
|
90 and 92 |
LVW unchanged |
Rat |
LV aggregate capillary |
|
LV myocyte CSA ↑19%–40% |
80 days |
length ↑7%–44% |
|
LV myocyte volume/nucleus |
|
|
|
↑61%–126% |
|
|
|
LV myocyte length/nucleus |
|
|
|
↑37%–64% |
|
LV aggregate capillary |
91 |
LVW unchanged, LVW/BW |
Rat |
|
|
↑8% |
300 g |
length ↑11% |
|
LV myocyte diameter ↑6% |
|
|
|
LV myocyte CSA ↑12% |
|
|
LV myocyte volume/nucleus ↑28%
LV myocyte length/nucleus ↑14%
HW = Heart weight; RVW, LVW = right and left ventricular weight; VW = total ventricular weight (RVW + LVW); BW = body weight; MCVP = maximal coronary vascular perfusion; CSA = cross-sectional area; NA= numerical density; LV = length density; LV aggregate capillary length was compared between surviving myocardium of post-MI rats and myocardium of sham-operated rats, which destined to survive after MI.
266 R. J. Tomanek & E. I. Dedkov
idea was also confirmed experimentally, since pharmacological prevention (with captopril, enalapril, losartan) of myocardial hypertrophy was able to completely restore a maximal myocardial perfusion.105,110 However, a recent finding showing that angiotensin II type 1 receptor blockade (valsartan), which reduced cardiac hypertrophy but did not limit cardiac interstitial fibrosis, is not able to improve coronary vasodilator reserve and minimal coronary vascular resistance.108 suggests that interstitial fibrosis can be an additional determinant regulating myocardial perfusion in post-infarcted hearts. The contribution of fibrosis is also suggested by recent findings from our laboratory which demonstrated that although arteriolar growth in the remaining myocardium of post-MI rats exceeded that detected in sham-operated animals, it was not associated with a proportional improvement in maximal myocardial perfusion and vasodilator reserve.101 Therefore, fibrosis may also contribute to a decline in maximal myocardial perfusion.
One apparent contributor to the limited post-infarction angiogenesis is the failure of growth factor increases to persist in the surviving myocardium. We found that increases in bFGF, VEGF and Tie-2 were transient, i.e. elevated only during the first few days after infarction.100 Similarly, we reported that increased levels of VEGF, flt-1, flk-1 in the surviving myocardium returned to control levels by seven days.111 Others have found increases in VEGF protein or mRNA to be limited to the ischemic border zone.112−114 Thus, the surviving myocardium distal to the border undergoes compensatory hypertrophy, but limited vascular growth, likely due to the failure of elevated growth factors to persist during the growth period. When rats with infarctions underwent heart rate reduction, we found they had higher VEGF, Flt-1 and bFGF levels than rats with infarction and non-reduced heart rates.109 These experiments support the idea that stretch resulting from increased diastolic dimensions could stimulate expression of angiogenic ligands and receptors.
In sum, the limited angiogenesis after infarction does not compensate for the reactive cardiac hypertrophy characteristic of the post-infarction period. Failure of sufficient angiogenesis to occur is largely due to limited and transient increases in growth factors and their receptors.
